GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS

Angela Stoddart, Megan E. McNerney, Elizabeth Bartom, Rachel Bergerson, David J. Young, Zhijian Qian, Jianghong Wang, Anthony A. Fernald, Elizabeth M. Davis, Richard A. Larson, Kevin P. White, Michelle M. Le Beau

Abstract


Therapy-related myeloid neoplasm (t-MN) is a distinctive clinical syndrome occurring after exposure to chemotherapy or radiotherapy.  t-MN arises in most cases from a multipotential hematopoietic stem cell or, less commonly, in a lineage committed progenitor cell.  The prognosis for patients with t-MN is poor, as current forms of therapy are largely ineffective.  Cytogenetic analysis, molecular analysis and gene expression profiling analysis of t-MN has revealed that there are distinct subtypes of the disease; however, our understanding of the genetic basis of t-MN is incomplete.  Elucidating the genetic pathways and molecular networks that are perturbed in t-MNs, may facilitate the identification of therapeutic targets that can be exploited for the development of urgently-needed targeted therapies.

Keywords


therapy-related myeloid neoplasms, genetic pathways, cytogenetic abnormalities, del(5q)

Full Text: PDF HTML

Mediterr J Hematol Infect Dis ISSN 2035-3006

$